Impressive ZEVALIN® Data Highlighted at 53rd Annual Meeting of the American ... TradersHuddle.com (press release) The authors have previously demonstrated that R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) is an effective regimen for indolent lymphoma, capable of inducing molecular remissions. Extended dosing of rituximab following induction, ... Multifaceted Repositioning Campaign for ZEVALIN(R) Unveiled at ASH 2011 ... |
